Newave Pharmaceutical LLC. and Guangzhou Lupeng Pharmaceutical Co., Ltd. have identified isoquinolines acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.

Philadelphia University (Jordan) has synthesized 2,4-disubstituted-thieno[2,3-d]pyrimidines acting as prostaglandin G/H synthase 2 (COX-2) inhibitors.

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.

Xinthera Inc. has divulged pyridinones acting as MAP kinase-activated protein kinase 2 (MAPKAPK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, metabolic diseases, inflammation and cardiovascular and cerebrovascular disorders.

State University of New Jersey and Tufts University have patented compounds with ability to modulate Mycobacterium tuberculosis (Mtb) response to high environmental chloride and acidic pH for Mtb growth inhibition reported to be useful for the treatment of tuberculosis.

Dice Alpha Inc. has synthesized phenyl acetamide compounds acting as interleukin-17A (IL-17A) production inhibitors reported to be useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.

Chan Zuckerberg Biohub and Stanford University have identified cyclin-dependent kinase 19 (CDK19) inhibitors reported to be useful for the treatment of triple-negative breast cancer.

Lung Therapeutics Inc. has divulged conjugates comprising epithelial sodium channel (ENaC) blockers (particularly, amiloride and benzamil) covalently linked to peptides to retain in lung tissues reported to be useful for the treatment of cystic fibrosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, primary ciliary dyskinesia, pulmonary emphysema, pneumonia and bronchiectasis.

Biogen Inc. and C4 Therapeutics Inc. have patented proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune and metabolic diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis, among others.

Medshine Discovery Inc. has presented benzylamino tricyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.